Breaking News, Trials & Filings

BMS, AZ’s Combo Diabetes Drug Gains Approval

Bristol-Myers Squibb and AstraZeneca received approval from the FDA for Kombiglyze XR for the treatment of type 2 diabetes in adults.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb and AstraZeneca received approval from the FDA for Kombiglyze XR for the treatment of type 2 diabetes in adults. Kombiglyze XR is the first once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering glycemic control across glycosylated hemoglobin levels (HbA1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG). Kombiglyze XR is indicated as an adjunct to diet and exercise to improve glycemic control in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters